Please login to the form below

Not currently logged in
Email:
Password:

fezolinetant

This page shows the latest fezolinetant news and features for those working in and with pharma, biotech and healthcare.

Bayer moves vilaprisan into phase III trials for uterine fibroids

Bayer moves vilaprisan into phase III trials for uterine fibroids

have acquired Ogeda and its phase IIa candidate Fezolinetant.

Latest news

  • Astellas agrees €800m deal to buy Belgian biotech Ogeda Astellas agrees €800m deal to buy Belgian biotech Ogeda

    Astellas agrees 800m deal to buy Belgian biotech Ogeda. Will pay another 300m if fezolinetant meets clinical and regulatory targets. ... Astellas is paying 500m upfront and up to 300m extra in clinical and regulatory milestones for Ogeda (formerly known

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    Fezolinetant successfully completed a phase 2a study in January in 80 menopausal women. ... In this case $319m is dependent on clinical and regulatory outcomes of fezolinetant.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics